CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [*****] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE THE REGISTRANT ACTUALLY TREATS THAT INFORMATION AS CONFIDENTIAL] REVENUE INTEREST PURCHASE AGREEMENT dated as of December 29, 2023 among...Revenue Interest Purchase Agreement • March 19th, 2024 • ImmunityBio, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 19th, 2024 Company Industry JurisdictionThis REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of December 29, 2023, by and among ImmunityBio, Inc., a Delaware corporation (the “Company”), the Purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”) and Infinity SA LLC, as collateral agent and administrative agent for the Purchasers (the “Purchaser Agent”).
REVENUE INTEREST PURCHASE AGREEMENT dated as of September 12, 2022 among ADAPTIVE BIOTECHNOLOGIES CORPORATION, the Purchasers from time to time party hereto and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as Purchaser AgentRevenue Interest Purchase Agreement • September 12th, 2022 • Adaptive Biotechnologies Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledSeptember 12th, 2022 Company Industry Jurisdiction
REVENUE INTEREST PURCHASE AGREEMENT dated as of December 8, 2020 among MIRUM PHARMACEUTICALS, INC., the Purchasers from time to time party hereto and MULHOLLAND SA LLC, as Purchaser AgentRevenue Interest Purchase Agreement • December 10th, 2020 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledDecember 10th, 2020 Company Industry JurisdictionThis REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of December 8, 2020, by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”) and Mulholland SA LLC, as collateral agent and administrative agent for the Purchasers (the “Purchaser Agent”).
REVENUE INTEREST PURCHASE AGREEMENT dated as of June 26, 2019 among ESPERION THERAPEUTICS, INC., the Purchasers from time to time party hereto and Eiger III SA LLC, as Purchaser AgentRevenue Interest Purchase Agreement • June 26th, 2019 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 26th, 2019 Company Industry JurisdictionThis REVENUE INTEREST PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of June 26, 2019, by and among Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), the Purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”) and Eiger III SA LLC, as collateral agent and administrative agent for the Purchasers (the “Purchaser Agent”).